(PharmaNewsWire.Com, April 26, 2019 ) The global antimicrobial susceptibility testing market is expected to reach USD 3.47 Billion by 2022 from USD 2.71 Billion in 2017, at a CAGR of 5.1%.
Factors such as increasing prevalence of infectious diseases across the globe, emergence of antimicrobial resistance caused due to drug overuse, increasing initiatives by government organizations towards improving the detection and control antimicrobial resistant species, and improving growth opportunities in emerging markets are boosting the demand for antimicrobial susceptibility testing products.
This report broadly segments the antimicrobial susceptibility testing (AST) market into product, method, type, application, end user, and region.
The report covers the antimicrobial susceptibility testing market across four key geographies, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW).
North America is expected to dominate the global AST market primarily due to easy accessibility and better adoption of technologically advanced susceptibility testing methods and products. The increasing prevalence of antimicrobial resistance in North America is another key factor supporting the growth of this regional segment in the global market.
The Asia Pacific is expected to grow at the fastest CAGR as markets in developed countries are increasingly becoming saturated and manufacturers and suppliers of AST products are shifting their focus towards the Asian market.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
